

Delirium de Réanimation

Tarek Sharshar

t.sharshar@ghu-paris.fr



Encephalopathy



*Disorder
of consciousness*


+

*Abnormal
Electroencephalogram*

➤ Coma

➤ Delirium

Encephalopathy



Complete the neurological examination


- Focal neurological sign
- Abnormal movements (seizures...)
- Neck stiffness
- Flapping (delirium)
- Brainstem reflexes (coma)
- Dysautonomia

General examination

- Vital signs
- Risk factors for encephalopathy
- Seek for the medical cause


Consequence of medical condition, substance intoxication or withdrawal

Subtypes of delirium




- **Hyperactive delirium**: agitation, aggression, hallucination and disorientation
- **Hypoactive delirium**: prostration, motor slowness, apathy, lethargia and withdrawal from interactions
- **Mixed delirium**: fluctuation between hyperactive and hypoactive subtypes

Hypoactive delirium




- Hypoactive delirium (HD) is **the most frequent subtype** of delirium
- HD can be easily misdiagnosed, necessity of routine detection by validated delirium scales
- **Age, dementia and severity of critical illness** increase the risk of HD
- HD is associated with **increased mortality** and impaired cognitive or functional outcomes
- **No specific treatment than those proposed in delirium**

Time distribution




EEG features



- **Most frequent EEG features:** Generalized slowing with increased theta and delta activity
- **Marker of severe encephalopathy:** Periodic discharges, triphasic waves, burst suppression, electrographic seizures less frequent but markers of severity
- **Delirium is characterized** by decreased variability in quantitative EEG and impaired connectivity.
- **EEG correlates of delirium:** Electrographic seizure more frequently seen in ICU patients with delirium
- **Prognostic predictors:** Absence of reactivity +++++
- **Delirium predictor:** Generalised slowing and absent reactivity

When doing an EEG in delirium?



- No clear recommendation
- Standard versus continuous EEG?
- Abnormal movement suggesting seizure
- Pro-epileptogenic factors (neurotoxic drugs, withdrawal...)
- Persistent encephalopathy
- Treating electrographic seizure (Yes?)
- Evaluating risk of delirium
- Prognostic evaluation

CAM-ICU Flowsheet

Confusion Assessment Method for the ICU

1

Acute change or fluctuating course of mental status

Is there an acute change from mental status baseline?
or
Has the patient's mental status fluctuated during the past 24 hours?

NO

YES

2

Inattention

"Squeeze my hand when I say the letter 'A.'"

Read one of the following sequences of letters:

SAVEAHAART or CASABLANCA or ABADBADAA

ERRORS: No squeeze with 'A' or squeeze on letter other than 'A'

If unable to complete letters → use pictures

0-2 Errors

>2 Errors

3

Altered level of consciousness

Current RASS level

RASS = 0

RASS other than 0

4

Disorganized thinking

1. Will a stone float on water?
2. Are there fish in the sea?
3. Does one pound weigh more than two?
4. Can you use a hammer to pound a nail?
5. "Hold up this many fingers" (Hold up 2 fingers)
"Now do the same thing with the other hand" (Do not demonstrate)
*If patient unable to move both arms, instead use "Add one more finger"

0-1 Error

> 1 Error

Not Delirious

Delirious

Must have Feature 1 and Feature 2 and either Feature 3 or Feature 4

ICU Delirium Screening Checklist

The Intensive Care Delirium Screening Checklist


Checklist Item	Description
Altered level of consciousness ^a	
A	No response
B	Response to intense and repeated stimulation
C	Response to mild or moderate stimulation
D	Normal wakefulness
E	Exaggerated response to normal stimulation
Inattentiveness	Difficulty following instructions or easily distracted
Disorientation	To time, place, or person
Hallucination-delusion- psychosis	Clinical manifestation or suggestive behavior
Psychomotor agitation or retardation	Agitation requiring use of drugs or restraints, or slowing
Inappropriate speech or mood	Related to events or situation, or incoherent speech
Sleep/wake cycle disturbance	Sleeping <4 hours/day, waking at night, sleeping all day
Symptom fluctuation	Symptoms above occurring intermittently
Total score	0 to 8

Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study

	Prevalence among participants (N=1040)	Frequency among delirium days (N=4187)	Duration among participants affected
Any delirium	740 (71%)	4187 (100%)	4 (2-7)
Hypoxic	579 (56%)	2247 (54%)	3 (1-5)
Septic	534 (51%)	2405 (57%)	3 (2-6)
Sedative-associated	663 (64%)	2634 (63%)	3 (1-5)
Metabolic	260 (25%)	1149 (27%)	3 (1-6)
Unclassified	224 (22%)	591 (14%)	2 (1-3)

Data are n (%) or median (IQR).

Table 2: Prevalence and duration of delirium phenotypes



Predeleeric score

Formula for PRE-DELIRIC model

Risk of delirium = $1/(1+\exp(-6.31$
+ 0.04 × age
+ 0.06 × APACHE-II score
+ 0 for non-coma or 0.55 for drug induced coma or 2.70 for miscellaneous coma or 2.84 for combination coma
+ 0 for surgical patients or 0.31 for medical patients or 1.13 for trauma patients or 1.38 for neurology/neurosurgical patients
+ 1.05 for infection
+ 0.29 for metabolic acidosis
+ 0 for no morphine use or 0.41 for 0.01-7.1 mg/24 h morphine use or 0.13 for 7.2-18.6 mg/24 h morphine use or 0.51 for >18.6 mg/24 h morphine use
+ 1.39 for use of sedatives
+ 0.03 × urea concentration (mmol/L)
+ 0.40 for urgent admission))

The scoring system's intercept is expressed as -6.31; the other numbers represent the shrunken regression coefficients (weight) of each risk factor.

Causes

1. Primary CNS disorders
2. Epilepsia
3. Organ failure (Renal, Liver, Heart, Respiratory..)
4. Metabolic disturbances/ Dehydratation
5. Hypoxemia/acido-basis disturbances
6. Drugs side-effects (AB etc..)
7. Withdrawal (druges, alcohol...)
8. Deficiencies (Vitamines)
9. Endocrinopathies
10. Infection
11. Pain/Retention/Discomfort/Sleep deprivation/anxiety...


Brain Imaging

EEG

CSF


Standard biological tests

Risk factors and pathophysiology





Pathophysiology of SAE

Vascular changes




Neuroinflammatory changes

Neuroinflammatory process





Neurotoxic





No biomarker of microglial immunophenotype

Ischemic process in SAE

Systemic HD changes
Autoregulation




Altered microperfusion



FLAIR



DWI




ADC



Occlusion


coupling

When doing a brain imaging?



- No clear recommendation
- Focal neurological signs
- Abnormal movements
- No obvious causes
- Persistent delirium

Outcomes




- **Increased Mortality**: ICU, in-Hospital, at one-year
- **Long-term cognitive impairment**: proportional relationship with delirium duration
- **Long-term psychological disorders**: delirium is a risk factor of PTSD



A causal relationship?

PATIENTS' TRAJECTORIES



USEFUL SCORES

RASS or SAS
GCS & FOUR
CAM-ICU(-7) or ICDSC

RASS or SAS
FOUR
CRS-r
CAM-ICU(-7) or ICDSC

4AT
MMSE or MoCA

Cognition: MMSE, MoCA, RBANS
Anxiety & Depression: HADS, BDI
Post-traumatic stress disorder: PCL-5
Quality of life: EQ-5D-3/5L, SF-12/36
Functional independence: ADL/IADL

ABCDEF Bundle

A

Assess, prevent & manage pain

- CPOT or BPS to assess pain, insure adequate pain control
- Use of regional anesthesia and nonopioid adjuncts
- Analgesia-based sedation techniques with fentanyl

B

Both SAT & SBT

- Daily linked SAT and SBT
- Multidisciplinary coordination of care
- Faster liberation from MV

C

Choice of sedation

- Targeted light sedation when sedation necessary
- Avoidance of benzodiazepines
- Dexmedetomidine if high delirium risk, cardiac surgery, MV weaning

D

Delirium monitoring & management

- Routine CAM-ICU or ICDSC assessments
- Nonpharmacologic intervention, including sleep hygiene
- Dexmedetomidine or antipsychotic if hyperactive symptoms

E

Early mobility & exercise

- Physical and occupational therapy assessment
- Coordinate activity with SAT or periods of no sedation
- Progress through range of motion, sitting, standing, walking, ADLs


F

Family engagement & empowerment

- Reorientation, provision of emotional and verbal support
- Cognitive stimulation, participation in mobilization
- Participation in multidisciplinary rounds




Early Mobilization in ICU



Intervention	Mortality	Prevention of delirium	Duration of delirium	Duration of MV/LOS	Long-term psychological disorders	Long-term cognitive disorders	Long-term Quality of Life
ICU/RCT/2009	No effect	Not tested	Reduction	Reduction	Not tested	Not tested	Not tested
Surgical ICU/RCT/2016	Trend for hospital mortality	Not tested	Reduction	Reduction of IOS	Not tested	Not tested	No effect
ICU/RCT/2023	Not tested	Yes	Reduction	Reduction	Not tested	Yes	Trend to better QoL (physical)
ICU/RCT/2024	No effect	Not tested	Not tested	No effect	No effect	No effect	No effect



Non-pharmacological intervention in ICU



- Family participation
- ABCDEF bundle
- Delirium early detection protocol
- Multicomponent
- Light noise blocking (improves sleep)

- Bright light therapy
- Architectural intervention
- Flexible family visitation (Rosa et al JAMA 2029)
- Massage
- Quiet time protocol
- Cognitive stimulation



PREVENTION


Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium

The REDUCE Randomized Clinical Trial

	2-mg Haloperidol (n = 732)	Placebo (n = 707)
Primary analysis, days alive at 28 days, median (IQR)	28 (28 to 28)	28 (28 to 28)
Survival, No. (%)		
28 d	610 (83.3)	585 (82.7)
90 d	579 (79.1)	556 (78.6)
28-Day end points		
Incidence of delirium, No. (%)	244 (33.3)	233 (33.0)
No. of delirium- and coma-free, median (IQR), d ^b	26 (17 to 28)	26 (19 to 28)
No. of delirium-free, median (IQR), d ^b	28 (22 to 28)	28 (23 to 28)
No. of coma-free, median (IQR), d ^b	27 (22 to 28)	27 (23 to 28)
No. of days to occurrence of delirium, median (IQR) ^b	3 (2 to 6)	3 (2 to 6)
Duration of mechanical ventilation, median (IQR), d	2 (0 to 6)	2 (0 to 5)

Haloperidol for treating delirium

Intervention	Mortality	Duration of delirium	Duration of MV/LOS	Long-term psychological disorders	Long-term cognitive disorders	Long-term Quality of Life
ICU/RCT/2018	ICU/hospital/ 3-months					
ICU/RCT/2023 AID-ICU	3-months					
ICU/RCT/2023 AID-ICU (Pre-planned Bayesian)	Hospital	Coma & delirium	Days alive without MV			
ICU/RCT/2023 AID-ICU (ancillary)	1-year					
ICU/RCT/2023 Euridice			Trends to reduce LOS			
ICU/RCT/2024 MIND-USA	3 and 12- months					



- Dose: 2,5 mg/8h in average
- Side-effects (ECG)
- Contraindicated in **catatonia**

- Motoric immobility (catalepsy, waxy flexibility, stupor)
- Excessive motor activity (purposeless, not influenced by external stimuli)
- Extreme negativism (rigid posture, resistance to instructions, gegenhalten, mutism)
- Peculiarities of voluntary movement (grimacing, bizarre postures, stereotyped movements)
- Echolalia or echopraxia

Dexmedetomidine for preventing or treating delirium


Intervention	Mortality	Delirium prevention	Delirium duration	Duration of MV/LOS
ICU/RCT/2016 SPICE III	ICU/hospital/ 3- months			
METANALYSIS				
MIDEX&PRODEX	Hospital		More cooperative with Dex	Days alive without MV
DEX vs MID	1-year			
DEX-LORAZEPAM				
DEX-SEPSIS				
DEX-AGITATED DELIRIUM				MV
DEX-ELDERLY-CARDIAC SURGERY				



No effect




Good effect



Not tested



Other drugs for preventing or treating delirium




- Minocycline (to b confirmed)
- Thiamine
- Reducing sedation
- BZD (Dex?) for alcohol withdrawal

- Statins
- Rivastigmine
- Melatonin




The KISS trial



- Control of the risk factors
- Treatment of the cause
- Think of alternative diagnosis

Conclusions




- **A frequent and severe complication** of critical illness and ICU management
- **Multifactorial**
- Associated with **short and long-term bad outcomes**, especially **hypoactive delirium**
- **To be detected routinely** with validated scales
- Prevention based on **reducing risk factors** (sedation and immobility).
- **Etiological treatment +++**
- Interest of **Dexmedetomidine** for helping discontinuation of sedation.
- **Antipsychotic drugs** if only agitation (or hallucination) but contra-indicated in catatonia (a differential diagnosis of delirium)



Quelques réflexions....

Dysfonction amygdalienne





KISS trial: Keppra in septic shock

ANXIETY (Panicu study)

Respiratory failure and delirium were the two most frequent organ failure






TABLE 4. Adjusted Analyses of the Association of State-Trait Anxiety Inventory State Questionnaire (From 20 to 80) Score With New Organ Failure After Day 1


Variables	OR (95% CI)	p
Model adjusted for SAPS II and SOFA at admission		
STAI-State ≥ 40	1.94 (1.18–3.18)	0.009
SAPS II (per point value)	1.03 (1.01–1.05)	0.005
SOFA score (per point value)	1.21 (1.05–1.39)	0.009
Model adjusted for SAPS II and SOFA at admission and dyspnea variables ^a		
STAI-State ≥ 40	1.72 (1.03–2.87)	0.038
SAPS II (per point value)	1.03 (1.01–1.05)	0.007
SOFA score (per point value)	1.22 (1.05–1.40)	0.007
Dyspnea Visual Analogic Scale (per point value)	1.06 (0.98–1.15)	0.13
Paco ₂ ≥ 45 mm Hg	1.27 (0.69–2.36)	0.45
Subgroup analysis according to SOFA value at admission, adjusted for SAPS II		
STAI-State ≥ 40 for patients without organ dysfunction at admission	2.02 (1.01–4.06)	0.048
STAI-State ≥ 40 for patients with organ dysfunction at admission	2.13 (1.03–4.39)	0.040
Interaction test		0.99

OR = odds ratio, SAPS = Simplified Acute Physiology Score, SOFA = Sequential Organ Failure Assessment, STAI-State = State-Trait Anxiety Inventory State questionnaire (from 20 to 80).
^aPost hoc analysis.
 C-index for the model adjusted for SAPS II and SOFA at admission: 0.698.
 C-index for the model with SAPS II and SOFA only: 0.676.
 C-index difference, 0.02; bootstrap 95% CI, 0.0002–0.070; p 0.048.
 Continuous net reclassification index, 0.297; bootstrap 95% CI, 0.081–0.516; p 0.005.
 C-index for the model adjusted for SAPS II and SOFA at admission and dyspnea variables: 0.703.



TANDEX trial: treatment of anxiety by DEX

Deep sedation



- It is required in more than **30% of critically ill patients** over the first 7 days
- It is required in **most severe critically ill patients** who are at risk of **neurological deterioration**
- Deep sedation can **mask neurological deterioration**
- It is associated with **increased mortality**
- It is associated with **delayed awakening, delirium and long-term psycho-cognitive disorders**

- ICU-mortality is associated
 - absent cough reflex,
 - heterogeneous pattern of abolition of brainstem reflexes
 - increased SSEP intracranial interlatency are associated with
- altered mental status after discontinuation of sedation is related
 - early abolition of oculocephalic reflex

ProReTro multicenter observational study

Multimodal assessment at day 3 of deep sedation


261 patients (brain injured: 139 (53%))

Primary outcome: medullar SSEP P14 > 16 ms associated with day 28 mortality


P14 latency at Day 3	Survivor (n=211)	Dead (n=53)
< 16 ms	77%	49%
> 16 ms	23%	51%

Pr Overall survival


	Hazard ratio	IC	p
P14 latency > 16 ms	2.98	[1.71-5.18]	0.0001
SAPS-II	1.01	[0.99-1.03]	0.41
GCS at admission	1.02	[0.95-1.09]	0.59
Brain injury	0.64	[0.31-1.30]	0.22



ProReTro multicenter observational study



The Paradigm



Clinical case

A 55 years old man was hospitalised for a septic shock. Blood culture were positive to *Staphylococcus aureus* and CSF analysis showed an aseptic meningitis. At admission, neurological examination was normal as well as MRI of the brain and spine. Transoesophageal cardiac ultrasound only showed a thrombus in the left atria. He also underwent surgery for a septic arthritis of the right knee. A right jugular catheter could not be put. A goitre was also noticed. Vasopressor and mechanical ventilation were discontinued the 3rd and 5th days from admission. The patient was treated with methicillin and heparin.



Day 8, the patient developed agitation and delirium. Neurological examination showed

1. **A weakness of the right arm,**
2. **A slight right central facial palsy,**
3. **A ptosis and miosis of the right eye.**
4. **The right arm was also oedematous.**
5. The brain CT scan and CSF analysis were normal. EEG showed a slow cortical activity. Biochemical screening showed a moderate renal insufficiency. Blood culture were negative.




Clinical case

1. Left pre-rolandic lesion
2. Thrombosis of right jugular vein
3. Orbenin overdose



Clinical case

- Mme X..., 53 years old, treated with CS et I- for LED, is admitted for ARF related to a thrombotic microangiopathy. Occurrence of a hyperactive delirium: « **on me vole mon enfant, les médecins me volent mon enfant...** »




Thank you For your Attention !

Tarek Sharshar

t.sharshar@ghu-paris.fr



First conclusion



- **Prevalence**
 - Historically: 60 to 80%
 - Nowadays: 25 to 45% (MV or shock)
- **Phenotypes**
 - Hyperactive, hypoactive or mixed
 - Hypoactive more frequent in elderly and worst outcome
- **Validated scores**
 - CAM-ICU, ICU-DSC...
- **Risk factors**
 - Predeliric score
 - Age, preexisting mental/neurological disorders, sepsis, sedation, metabolic disorders, drug overdoses or withdrawal...
- **Complications**
 - Increased short and long-term mortality
 - Increased long-term psychocognitive impairment

EEG in septic patients

